![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
BJ Ring, J Catlow, TJ Lindsay, T Gillespie, LK Roskos, BJ Cerimele, SP Swanson, MA Hamman and SA Wrighton
Department of Drug Metabolism and Disposition, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA.
The formation kinetics of 2-hydroxymethyl olanzapine (2-OH olanzapine), 4'-N-oxide olanzapine (N-O olanzapine) and 4'-N-desmethyl olanzapine (NdM olanzapine) were analyzed in vitro. Biphasic kinetics were observed for formation of 2-OH and NdM olanzapine. The high-affinity enzyme responsible for 2-OH olanzapine formation by two human liver samples exhibited an intrinsic clearance (CLint) of 0.2 microliter/min/mg. NdM olanzapine formation by two human liver samples exhibited a CLint of 1.0 microliter/min/mg for the high affinity enzyme. The formation of N-O olanzapine was linear up to 300 microM olanzapine, yielding a CLint of 0.32 to 1.70 microliters/min/mg. The formation of 7-hydroxy olanzapine (7-OH olanzapine) exhibited an apparent Km of 24.2 microM. The rates of 2-OH olanzapine formation correlated with CYP2D6 levels and activity, and it was formed to the greatest extent by cDNA-expressed CYP2D6. N-O olanzapine formation correlated with human liver flavin-containing monooxygenase (FMO3) levels and activity. NdM olanzapine and 7-OH olanzapine formation correlated with CYP1A2 catalytic activities and they were formed to the greatest extent by expressed CYP1A2. These results suggest that CYP1A2 catalyzes NdM olanzapine and 7-OH olanzapine formation, CYP2D6 catalyzes 2-OH olanzapine formation and FMO3 catalyzes N-O olanzapine formation.
This article has been cited by other articles:
|
|
 |
|
  P. Morissette, R. Hreiche, L. Mallet, D. Vo, E. E. Knaus, and J. Turgeon Olanzapine prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current J Psychopharmacol, September 1, 2007; 21(7): 735 - 741. [Abstract] [PDF]
|
|
|
|
 |
|
 M. J. Karjalainen, P. J. Neuvonen, and J. T. Backman Rofecoxib Is a Potent, Metabolism-Dependent Inhibitor of CYP1A2: Implications for in Vitro Prediction of Drug Interactions Drug Metab. Dispos., December 1, 2006; 34(12): 2091 - 2096. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Gardiner and E. J. Begg Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice Pharmacol. Rev., September 1, 2006; 58(3): 521 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. F. Rehmel, J. A. Eckstein, N. A. Farid, J. B. Heim, S. C. Kasper, A. Kurihara, S. A. Wrighton, and B. J. Ring INTERACTIONS OF TWO MAJOR METABOLITES OF PRASUGREL, A THIENOPYRIDINE ANTIPLATELET AGENT, WITH THE CYTOCHROMES P450 Drug Metab. Dispos., April 1, 2006; 34(4): 600 - 607. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-C. Chiu, H.-Y. Lane, M.-C. Huang, H.-C. Liu, M. W. Jann, Y.-Y. Hon, W.-H. Chang, and M.-L. Lu Dose-Dependent Alternations in the Pharmacokinetics of Olanzapine During Coadministration of Fluvoxamine in Patients With Schizophrenia J. Clin. Pharmacol., December 1, 2004; 44(12): 1385 - 1390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Williams, R. Hyland, B. C. Jones, D. A. Smith, S. Hurst, T. C. Goosen, V. Peterkin, J. R. Koup, and S. E. Ball DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS Drug Metab. Dispos., November 1, 2004; 32(11): 1201 - 1208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Stevens, R. J. Melton, M. J. Zaya, and L. C. Engel Expression and Characterization of Functional Dog Flavin-Containing Monooxygenase 1 Mol. Pharmacol., February 1, 2003; 63(2): 271 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Cashman and J. Zhang Interindividual Differences of Human Flavin-Containing Monooxygenase 3: Genetic Polymorphisms and Functional Variation Drug Metab. Dispos., October 1, 2002; 30(10): 1043 - 1052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Ring, S. A. Wrighton, S. L. K. Aldridge, K. Hansen, B. Haehner, and L. A. Shipley Flavin-Containing Monooxygenase-Mediated N-Oxidation of the M1-Muscarinic Agonist Xanomeline Drug Metab. Dispos., October 1, 1999; 27(10): 1099 - 1103. [Abstract] [Full Text]
|
|
|
|
|
|
J.-d. Huang, W.-C. Guo, M.-D. Lai, Y. L. Guo, and G. H. Lambert Detection of a Novel Cytochrome P-450 1A2 polymorphism (F21L) in Chinese Drug Metab. Dispos., January 1, 1999; 27(1): 98 - 101. [Abstract] [Full Text]
|
|
|
|
|
|
S. S. Surapaneni, M. P. Clay, L. A. Spangle, J. W. Paschal, and T. D. Lindstrom In Vitro Biotransformation and Identification of Human Cytochrome P450 Isozyme-Dependent Metabolism of Tazofelone Drug Metab. Dispos., December 1, 1997; 25(12): 1383 - 1388. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. C. Stevens, R. B. White, S. H. Hsu, and M. Martinet Human Liver CYP2B6-Catalyzed Hydroxylation of RP 73401 J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1389 - 1395. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. C. Tugrul and J. A. Bennett Olanzapine: Safety Profile and Dosing Strategies Journal of the American Psychiatric Nurses Association, February 1, 1997; 3(1): S14 - S17. [PDF]
|
|
|
|
|
|
K. Kassahun, E. Mattiuz, E. Nyhart Jr., B. Obermeyer, T. Gillespie, A. Murphy, R. M. Goodwin, D. Tupper, J. T. Callaghan, and L. Lemberger Disposition and Biotransformation of the Antipsychotic Agent Olanzapine in Humans Drug Metab. Dispos., January 1, 1997; 25(1): 81 - 93. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
